Position in MNPR
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$128,607
+$93,706 QoQ
Shares Held
1,389
+118.1% QoQ
Ownership
0.021%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MNPR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MEEDER ASSET MANAGEMENT INC holds $6,513,506 across 35 Biotechnology names. MNPR ranks #6 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,156 | $4,462,048 | |
| 2 | CAI |
Caris Life Sciences, Inc.
|
34,035 | $606,501 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,570 | $472,613 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
5,009 | $186,384 | |
| 5 | TWST |
Twist Bioscience Corp
|
1,571 | $161,624 | |
| 6 | MNPR |
Monopar Therapeutics
This page
|
1,389 | $128,607 | |
| 7 | RAPP |
Rapport Therapeutics, Inc.
|
2,774 | $115,592 | |
| 8 | CRVS |
Corvus Pharmaceuticals, Inc.
|
6,055 | $90,461 |
All Filings in MNPR
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $128,607 | 1,389 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $34,901 | 637 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $64,908 | 994 | Shares | Sole | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||